

National Oesophago-Gastric Cancer Audit

Oxford University Hospitals NHS Foundation Trust

Thames Valley, Cancer Alliance

Management of High Grade Dysplasia patients

Time period: 2018-22

| | | Cancer Alliance | National |
|---|-----|-----------------|----------|
| Number of High Grade Dysplasia patients in audit | 51 | | 1120 |
| | | Cancer Alliance | National |
| Method of Diagnosis | | | |
| – First diagnosis confirmed by second pathologist | N/A | 93.3% | 90.0% |
| Treatment planning | | | |
| – HGD plan discussed at MDT | N/A | 100.0% | 93.0% |
| – Treatment plan for active treatment | N/A | 88.0% | 82.0% |
| First treatment | | | |
| – Endoscopic therapy (such as endoscopic resection) | N/A | 86.0% | 78.0% |
| – Surveillance | N/A | 6.0% | 11.0% |


NOTE: Percentages have been calculated based on the number of patients with recorded data for each variable and not the total number of patients in the Cancer Alliance.

Management of oesophago-gastric cancer patients

Time period: 2020-2022


| | Organisation | | National |
|---|--------------|-------|----------|
| Number of oesophago-gastric (OG) cancer patients in audit | 233 | | 19,865 |
| Case ascertainment for OG cancer (%) | 85-100% | | |
| Method of Diagnosis | | | |
| – Patients diagnosed after an emergency admission** ** Percent figure accounts for differences in mix of patients across organisations | 21 | 9.0% | 13.1% |
| – Patients with referral source reported as unknown | 0 | 0.0% | 1.4% |
| Pre-treatment staging of cancer | | | |
| – Patients having staging CT scan recorded | 226 | 97.0% | 94.0% |
| Treatment planning | | | |
| – Patients having a plan for curative treatment | 101 | 43.4% | 37.2% |
| – Patients having a plan for non-curative treatment | 132 | 56.7% | 62.8% |
| – Patients with non-curative plans having chemotherapy or radiotherapy | 78 | 59.1% | 34.7% |

90-day mortality rate



| Trust | Number | Adjusted % |
|--|--------|------------|
| Oxford University Hospitals NHS Foundation Trust | 259 | 1.39 |

30-day mortality rate



| Trust | Number | Adjusted % |
|--|--------|------------|
| Oxford University Hospitals NHS Foundation Trust | 259 | 0.42 |

Outcomes for OG cancer patients who have curative surgery

Time period: 2019-2022

| | Organisation | National |
|--|--------------|----------|
| Number of patients having surgery | 259 | 5452 |
| Length of stay, median (days) | 9 | 10 |
| Operations in which 15 or more lymph nodes were examined (%) | 95.7% | 90.1% |
| 30-day postoperative mortality (%) | 0.4% | 1.5% |
| 90-day postoperative mortality (%) | 1.4% | 2.9% |
| Oesophageal surgery | | |
| Number of patients having oesophageal surgery | 189 | N/A |
| Oesophageal patients with positive longitudinal margins (%) | 1.0% | 4.9% |
| Oesophageal patients with positive circumferential margins (%) | 19.0% | 21.5% |
| Gastric surgery | | |
| Number of patients having gastric surgery | 70 | N/A |
| Gastric patients with positive longitudinal margins (%) | 12.8% | 9.8% |